Inhibition of liver fibrosis by ellagic acid.
Chronic administration of carbon tetrachloride in liquid paraffin (1.7) ip; 0.15 ml, (20 doses) has been found to produce severe hepatotoxicity, as seen from the elevated levels of serum and liver glutamate-pyruvate transaminase, alkaline phosphatase and lipid peroxides. The chronic administration of carbon tetrachloride was also found to produce liver fibrosis as seen from pathological analysis as well as elevated liver-hydroxy proline. Oral administration of ellagic acid was found to significantly reduce the elevated levels of enzymes, lipid peroxide and liver hydroxy proline in these animals and rectified liver pathology. These results indicate that ellagic acid administration orally can circumvent the carbon tetrachloride toxicity and subsequent fibrosis.
Thresiamma
K C
KC
Amala Cancer Research Centre, Amala Nagar, Trichur, Kerala.
Kuttan
R
R
D000410:Alanine Transaminase / Q000097:blood; D000469:Alkaline Phosphatase / Q000097:blood; D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use*; D002251:Carbon Tetrachloride; D004610:Ellagic Acid / Q000627:therapeutic use*; D005260:Female; D008054:Lipid Peroxides / Q000097:blood; D008103:Liver Cirrhosis / Q000097:blood / Q000139:chemically induced / Q000517:prevention & control*; D051381:Rats; D017208:Rats, Wistar
D000975:Antioxidants; D008054:Lipid Peroxides; D004610:Ellagic Acid; D002251:Carbon Tetrachloride; D000410:Alanine Transaminase; D000469:Alkaline Phosphatase